43 0 2

Partnering

MacroGenics is pursuing alliances to participate in development of its proprietary product candidates and technology platforms.

Learn more

Company Highlights

  • Robust pipeline in oncology and autoimmune disorders
  • Partners include Takeda, Gilead, Servier, Pfizer and Boehringer Ingelheim
  • Fully-integrated biologics capabilities across product development process 
  • Strong financial position
  • Experienced leadership and highly collaborative corporate culture 
Learn more

Overview

Since its founding in 2000, MacroGenics has applied its world-class antibody capabilities to create life-changing medicines. The company’s innovative product candidates leverage its fully-integrated capabilities and its multiple, proprietary technology platforms.

Learn more

In the News

2011 News Archive

December 23, 2011 | Gazette.Net
MacroGenics, BrainScope Among Bioscience Winners

December 01, 2011 | Washington Business Journal
MacroGenics Inks Pharma Deal Worth up to $450 Million

December 01, 2011 | Fierce Biotech
MacroGenics Pockets $20M in $450 Deal with Servier

December 01, 2011 | Bio World
MacroGenics 'Serves' Early Stage Antibody Deal: Potential $450M

November 30, 2011 | "The Pink Sheet" Daily
Servier, MacroGenics Forge Option Deal for Cancer Drug

July 14, 2011 | Medpage Today
ADA: Drug Misses Type 1 Goal, but May Help Beta Cells

June 07, 2011
Why Diabetes Prevention Might Work When Treatment Doesn't

June 07, 2011 | Wall Street Journal
Trying to Prevent Type 1 Diabetes

April 28, 2011 | Inside Blood
DARTs Take Aim at BiTEs

January 18, 2011 | Nature Biotechnology
Boehringer Splashes out on Bispecific Antibody Platforms

News Archive: 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | View All